Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
DYAI

DYAI - Dyadic International Inc Stock Price, Fair Value and News

$0.86-0.02 (-2.27%)
Market Closed

9/100

DYAI

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

9/100

DYAI

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$0.72

Target 3M

$0.81

Target 6M

$0.76

DYAI Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

DYAI Price Action

Last 7 days

-3.4%

Last 30 days

-3.4%

Last 90 days

-26.5%

Trailing 12 Months

-43.8%

DYAI RSI Chart

DYAI Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

DYAI Valuation

Market Cap

31.1M

Price/Earnings (Trailing)

-4.24

Price/Sales (Trailing)

9.31

Price/Free Cashflow

-6.72

DYAI Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$0.72

Target 3M

$0.81

Target 6M

$0.76

DYAI Fundamentals

DYAI Revenue

Revenue (TTM)

3.3M

Rev. Growth (Yr)

-40.5%

Rev. Growth (Qtr)

20.48%

DYAI Earnings

Earnings (TTM)

-7.3M

Earnings Growth (Yr)

-871.2%

Earnings Growth (Qtr)

-10.16%

DYAI Profitability

Return on Equity

-281.83%

Return on Assets

-62.95%

Free Cashflow Yield

-14.87%

DYAI Investor Care

Shares Dilution (1Y)

22.30%

Diluted EPS (TTM)

-0.2

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20253.6M4.1M3.3M0
20242.3M1.8M3.4M3.5M
20233.3M3.4M3.0M2.9M
20222.6M2.3M2.5M2.9M
202102.2M2.4M2.3M
20201.6M1.7M1.7M1.6M
20191.5M1.7M1.9M1.7M
2018892.7K1.0M1.2M1.3M
2017000758.4K
Get all data in R, Python etc through our Historical Stock Data APIs

About Dyadic International Inc

DYAI
Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States. It utilizes its patented and proprietary C1 platform and other technologies to conduct research, development, and commercial activities for the development and manufacturing of human and animal vaccines and drugs, such as virus-like particles, protein antigens, ferritin nanoparticles, monoclonal antibodies, bi/tri-specific antibodies, fab antibody fragments, Fc-fusion proteins, biosimilars and/or biobetters, and other therapeutic enzymes and proteins. The company offers DYAI-100, SARS-CoV-2-RBD antigen vaccine candidate towards a first-in-human Phase 1 clinical trial, is to demonstrate the safety in humans of a protein produced from C1-cell protein production platform. It has a research and development agreement with VTT Technical Research Centre of Finland, Ltd.; and strategic research services agreement with Biotechnology Developments for Industry in Pharmaceuticals, S.L.U., as well as co-development and marketing agreement with Fermbox Bio Inc to design, Develop, and commercialize animal free alternative proteins and biomaterials The company was founded in 1979 and is headquartered in Jupiter, Florida.
0
 CEO
 WEBSITEdyadic.com
 SECTORHealthcare
 INDUSTRYBiotechnology

Dyadic International Inc Frequently Asked Questions

DYAI is the stock ticker symbol of Dyadic International Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Dyadic International Inc is 31.12 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check DYAI's fair value in chart for subscribers.

The fair value guage provides a quick view whether DYAI is over valued or under valued. Whether Dyadic International Inc is cheap or expensive depends on the assumptions which impact Dyadic International Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for DYAI.

As of Wed Jan 28 2026, DYAI's PE ratio (Price to Earnings) is -4.24 and Price to Sales (PS) ratio is 9.31. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. DYAI PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, Dyadic International Inc has provided -0.06 (multiply by 100 for percentage) rate of return.